New RSV Vaccine Recommendations Simplify Decision-Making for Seniors

The CDC has updated its recommendations for respiratory syncytial virus (RSV) vaccines, simplifying the process for adults 60 years and older. Initially, shared clinical decision-making was emphasized, but this proved challenging, leading to confusion and delays. The revised recommendations now prioritize age-based criteria, with all adults 75 and older receiving a single dose of any FDA-approved RSV vaccine. For individuals aged 60 to 74, risk-based recommendations apply, with providers able to assess individual risk factors and offer vaccination accordingly. The CDC emphasizes the need for ongoing research to further refine risk factors and ensure continued flexibility in vaccination choices.